Recent studies from our laboratory have documented that global TSP-1 deletion in vivo reduces atherosclerotic lesion burden in ApoE–/– mice in response to both STZ-induced hyperglycemia (26) and exogenous leptin administration (27), mimicking obesity. The gene discussed is APOE; the disease is Hyperglycemia.